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Abstract
The detection of ancient DNA and lipid biomarkers has become established for the detection of tuberculosis 
and leprosy in archaeological material, including mummies. Recording the characteristic profiles of long-chain 
mycolic acids by fluorescence high-performance liquid chromatography (HPLC) has been developed to provide 
a highly specific method for the detection of ancient tuberculosis and leprosy. Initially, mycolate methylanthryl 
esters were analysed but these derivatives have been superseded by pyrenebutyric acid derivatives of penta-
fluorobenzyl esters. Long-chain compounds are released by an efficient non-aqueous alkaline extraction and 
acidic components are converted to stable pentafluorobenzyl esters, which can be preserved for immediate or 
future analysis. These long-chain components are fractionated into non-hydroxylated esters, mycolates and 
characteristic phthiocerols. The mycolate pyrenebutyrates are analyzed by fluorescence HPLC to produce profiles 
characteristic of mycobacterial disease. It is shown in this study that residual material from DNA determina-
tions, on mainly Turkish and Hungarian skeletons, can be used for the detection of mycolic acid biomarkers for 
tuberculosis and leprosy. The correlation between DNA and mycolic acids biomarker results was not precise, 
confirming the importance of using complementary methods. In one particular Turkish skeleton, with poor 
DNA preservation, mycolic acid analysis supported pathological changes indicative of leprosy.
Introduction
It has been shown that molecular biomarkers, such as DNA and characteristic lipids have good potential 
in systematic studies of ancient diseases, such as tuberculosis and leprosy (Donoghue 2009). The archaeo-
logical material investigated includes skeletons and mummies (Donoghue et al. 1998, 2010; Hershkovitz 
et al. 2008). The analysis of ancient DNA has allowed the detection and spoligotyping of Mycobacterium 
tuberculosis in Egyptian mummies (Zink et al. 2003).
 The analysis of a single biomarker, such as DNA, has limitations due to possible degradation and 
contamination. The use of stable lipid biomarkers has particular potential for the detection of ancient 
mycobacterial disease, since high molecular weight mycolic acids, for example, are totally distinct from 
anything found in mammalian tissue. Modern analytical methods are able to detect such lipids down to 
the femtomole level and the lack of any amplification reduces the contamination problem. Mycolic acid 
analysis, using high performance liquid chromatography (HPLC) of fluorescent derivatives, has been 
shown to be an excellent way to complement DNA detection in recognizing ancient tuberculosis (Dono-
ghue et al. 1998, 2010; Gernaey et al. 2001; Hershkovitz et al. 2008). The mycocerosic acid components 
of phthiocerol dimycocerosates can also be used to detect M. tuberculosis in skeletal material (Redman et 
al. 2009).
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 Archaeological samples have high intrinsic value and it is important to make best use of such mate-
rial. The present communication will show that it is possible to obtain mycolic acid lipid biomarkers 
from material from which DNA has already been extracted. The previous protocols, used to detect 
ancient M. tuberculosis mycolic acids for the first time (Donoghue et al. 1998; Gernaey et al. 1998, 2001), 
suffered from some instability of the chemical derivatives used so a whole new approach has been de-
vised. Mycolic acids are analyzed by fluorescence HPLC of stable pyrenebutyric acid (PBA) derivatives 
of pentafluorobenzyl (PFB) esters (Donoghue et al. 2010, Hershkovitz et al. 2008, Taylor et al. 2009). This 
procedure has been used, in combination with DNA analysis, to confirm the presence of tuberculosis 
in a 9000 year old mother and child from the Eastern Mediterranean (Hershkovitz et al. 2008) and the 
so-called Granville mummy, preserved in the British Museum (Donoghue et al. 2010). The presence of 
leprosy was confirmed in an Uzbek leper (Taylor et al. 2009). The intrinsic value of archaeological mate-
rial requires that information must be maximised and there appeared to be no reason why residues from 
DNA extraction should not be investigated for the presence of lipid biomarkers, such as mycolic acids.
Methods
The archaeological materials used (Table 1) were extracts available from previous studies (Donoghue 
et al. 2005, Molnár et al. 2006, Csóri et al. 2009, Marcsik et al. 2009, Donoghue, unpublished), in which 
DNA had been removed according to standard protocols (Donoghue et al. 2005). These extracts and 
standard M. tuberculosis and M. leprae were processed, as described previously (Donoghue et al. 2010, 
Hershkovitz et al. 2008, Taylor et al. 2009), to produce extracts suitable for HPLC analysis of mycolates 
as their PBA-PFB esters. HPLC separations were performed with a VWR Hitachi Elite LaChrom HPLC 
with an L-2130 pump and L-2480 fluorescence detector. Samples were dissolved in HPLC grade heptane 
(20-40 μl) in a 1.0 ml vial and-injected by an autosampler L-2200 (0.1-20 μl). The column was stabilised 
at 25 °C in an L-2300 column oven. Fractions were automatically collected on a Foxy Jr. fraction collector. 
Conditions for the HPLC analysis are shown in Table 2. Reverse phase columns were used for identifica-
tion of total mycolates and mycolate subclasses after the total mycolates were collected and separated 
into α-, methoxy- and ketomycolate subclasses on normal phase columns. 
Results and Discussion
The initial reverse phase HPLC profiles are shown in Figure 1a. The total mycolate fractions were col-
lected and analysed by normal phase HPLC, as shown in Figure 1b the relative proportions of each 
mycolate class are shown in Table 1. Fractions corresponding to α-, methoxy- and ketomycolates were 
subjected to further reverse phase HPLC as shown in Figure 2. HPLC profiles of mycolates from standard 
M. tuberculosis and M. leprae (Figs. 1, 2) are distinct but there is some overlap of components. The main 
distinguishing feature is the lack of methoxymycolates in M. leprae (Fig. 1b) but other notable differences 
are, for M. tuberculosis and M. leprae, the main ketomycolates have 87 and 83 carbons (Fig. 2c), respectively, 
and the α-mycolates have 80 and 78 carbons (Fig. 2a), respectively.
 The total mycolate reverse phase traces (Fig. 1a) included those (samples 4, 7 and 8) which resembled 
the leprosy standard. In the normal phase profiles of these samples (Fig. 1b, Table 1) there are small 
components corresponding to ketomycolates and in the region expected for methoxymycolates. Second 
reverse phase HPLC of the mycolate classes, from samples 4, 7 and 8, showed nothing attributable to 
methoxymycolates (Fig. 2b); samples 4 and 7 appeared to have ketomycolates similar to M. leprae but the 
extract from sample 8 was devoid of ketomycolates (Fig. 2c). Sample 9 produced an α-mycolate HPLC 
trace (Fig. 2a), resembling M. leprae, but the trace for the ketomycolates was inconclusive with only a 
very small peak corresponding to a C83 component (Fig. 2c). It is important to note, as indicated above, 
that the presence of a quantifiable amount of material (Table 1) in the region expected for methoxymy-
colates on normal phase HPLC (marked with “↓” in Figure 1b) does rule out the diagnosis of leprosy. 
For example, samples 4, 7, 8 and 9 showed small proportions (0.12-0.39, Table 1) of indistinct materials 
(Fig. 1b), which are not confirmed as methoxymycolates on reverse phase HPLC (Fig. 2b).
 The suggestion that mycolate analysis showed that sample 4 was a case of leprosy is particularly 
interesting, as the poor quality of the aDNA did not allow a diagnosis to be made using that biomarker 
(Table 1; Donoghue, unpublished). This skeleton (KK24/1a) was obtained from the same Turkish Byzantine 
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Table 1. Origin and results for archaeological samples. The ratios of individual mycolate types were measured 
by automatic integration; a number for methoxy-MA does not confirm its presence and the HPLC traces in 
Figures 1 and 2 must be consulted. The references marked with * contain no aDNA results; the quoted results 
are Donoghue, unpublished. Ancient leprosy DNA, has been found in a skeleton (KK20/1) from the same site 
as Sample 4 (KK24/1a) (Monod et al. 2009).
No. Date, place and code aDNA MA α-, methoxy- 
keto-MA ratio
Corre-
lation
Reference
1 7th-8th century Kiskundorozsma, 
Hungary KD 517
Lep+TB TB 1 : 0.44 : 0.33 +/− Molnár et al. 2006
2 7th-8th century Kiskundorozsma, 
Hungary KD 21 
TB TB 1 : 0.74 : 0.28 + Molnár et al. 2006
3 8th-9th century Byzantine, Turkey KK2/1a TB? TB 1 : 0.52 : 0.25 + Erdal 2004*
4 8th-9th century Byzantine, Turkey KK24/1a Poor 
DNA ?
Lep 1 : 0.15 : 0.30 − Erdal 2004*
5 15th century Szombathely, Hungary 6 TB ? 1 : 0.87 : 0.10 − Donoghue et al. 2005
6 15th century Szombathely, Hungary 10 Lep Lep+TB 1 : 0.42 : 0.99 +/− Donoghue et al. 2005
7 10th-11th century Püspökladány, 
Hungary 503
Lep+TB Lep 1 : 0.12 : 0.19 +/− Donoghue et al. 2005
8 Late 7th-9th century Szarvas Grexla, 
Hungary SG38
Lep Lep? 1 : 0.13 : 0.21 + Marcsik et al. 2009
9 10th century Hajdudorog-Gyulas, 
Hungary HG56
Lep Lep? 1 : 0.39 : 0.09 + Csóri, et al. 2009
10 8th century Kiskundorozsma, 
Hungary KD9018
Lep Lep+TB 1 : 1.00 : 1.46 +/− Molnár et al. 2006
11 19th century Crossbones, Southwark, 
London, UK 9
TB TB? 1 : 0.88 : 0.58 + Brickley et al. 1999*
12 10th-13th century Bjorned, Sweden A4 Lep+TB ? 1 : 0.87 : 0.30 − Donoghue et al. 2005
Table 2. Conditions for HPLC analysis of PBA PFB mycolates.
Conditions Column Gradient elution program
Flow rate: 1 ml/min.
Reverse phase: Alltech Alltima 81412 C18 analytical 
column, 3 μ, I.D. 4.6 mm × Length 50 mm 
Acetonitrile/tetrahydrofuran:
55 : 45 to 45 : 55 in 31 min 
Detector: 
Excitation 342 nm, 
emission 376 nm
Normal phase: Alltech Alltima 81414 silica analytical 
column, 3 μ, I.D. 4.6 mm × Length 50 mm
Heptane/ethyl acetate: 
100 : 0 to 99 : 1 in 1 min; 
99 : 1 to 97 : 3 in 30 min
source (Erdal 2004) as another sample (KK20/1), which gave a strong aDNA response for leprosy (Monod 
et al. 2009). Both of these skeletons showed comparable clear pathology, indicative of leprosy (Erdal 2004), 
so aDNA preservation can vary within a particular site.
 Evidence for the presence of TB was seen in samples 1, 2, 3 and 11, but some of the traces had un-
usual features (Figs. 1, 2). The mycolates from samples 2 and 11 gave normal phase HPLC traces with 
double peaks for each of the α-, methoxy- and ketomycolate types (Fig. 1b). This indicates that a type of 
degradation, called “racemisation”, has taken place to produce “diastereoisomers”, which are separable 
on normal phase chromatography. In the second reverse phase profiles (Fig. 2) peaks indicating α-, 
methoxy- and ketomycolates could be seen, but extra peaks (labeled ?) were observed in α-mycolates 
from sample 11 and methoxy- and ketomycolates for sample 3. The extra peaks eluted before those at-
tributable to M. tuberculosis and they may be due to partial degradation of the oxygenated mycolates.
 In the samples 6 and 10 the mycolate HPLC profiles show evidence for co-infection with TB and 
leprosy. Notably, these extracts are relatively rich in ketomycolates (Fig. 1b, Table 1); that from sample 
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6 corresponds well in size with that (C83) of M. leprae but the ketomycolate from sample 10 appears to 
contain both C83 and C85 components. Both samples 6 and 10 had recognizable methoxymycolate HPLC 
traces (Fig. 2b), supporting the presence of M. tuberculosis; the main α-mycolates had main C78 components, 
favoring M. leprae (Fig. 2a). Extracts of samples 5 and 12 have poorly defined profiles, which indicate a 
substantial degree of degradation, particularly for sample 5.
 It is interesting to correlate the above results with previous studies of ancient DNA (aDNA) (Table 1). 
Good correlation is seen with samples 2, 3, 8, 9 and 11, with 2, 3 and 11 confirming TB and 8 and 9 sup-
porting leprosy. Interesting disparities were observed for samples 1, 6, 7 and 10. For sample 1, both TB 
and leprosy were indicated by aDNA analysis, but the HPLC profiles (Figs. 1, 2) were in favor of only TB. 
Similarly, aDNA showed both diseases in sample 7, but lipid analysis suggested only leprosy. Conversely, 
samples 6 and 10 had only recognizable DNA for M. leprae but both diseases were discernible from the 
mycolate HPLC profiles (Figs. 1, 2). In sample 4, which had strong leprosy pathology, aDNA studies were 
inconclusive (Table 1), but reasonably clear HPLC mycolate profiles were recorded to indicate leprosy. 
Conversely, where conclusive aDNA results suggested TB and TB plus leprosy for samples 5 and 12, 
respectively (Table 1), the mycolate HPLC profiles (Figs. 1, 2) were uninformative. 
 The results summarized in Figures 1 and 2 demonstrate that residues remaining after DNA extrac-
tion are still a source of mycolic acid biomarkers for mycobacterial disease. This is not surprising as the 
aDNA extraction protocols are completely aqueous and mycolic acids are extremely hydrophobic. The 
recorded profiles do not all correlate precisely with standard material from M. tuberculosis and M. leprae 
(Figs. 1, 2). In previous studies on M. tuberculosis (Donoghue et al. 2010; Hershkovitz et al. 2008; Gernaey 
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Fig. 1. HPLC of PBA-PFB derivatives of MAs. a, Reverse phase HPLC of total mycolates. b, Normal phase 
HPLC of collected total mycolate fraction. See Table 1 for origin of samples 1 to 12. “TB std” and “Lep std” 
are standard mycolic acid profiles for M. tuberculosis and M. leprae, respectively. The arrow (“↓”) in Figure 1b 
indicates the absence of methoxymycolates in M. leprae.
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et al. 1998, 2001), it appeared that the mycolic acid content remained essentially undegraded, indicat-
ing that preservation of those samples was good. The HPLC results, shown here (Figs. 1, 2), are not so 
pristine, suggesting various levels of degradation. It is not possible to conclude, from the present study, 
that mycolic acid lipid biomarkers are more robust than aDNA. The main finding is that the joint analysis 
of both aDNA and mycolate biomarkers, on the same sample, provides an enhanced level of diagnostic 
information.
 In exploiting the use of molecular biomarkers for ancient mycobacterial disease, it is important to 
ensure that a rigorous and objective approach is taken. In a recent critique of ancient DNA studies (Wilbur 
et al. 2010), a number of concerns were expressed and a detailed response has been published to allay 
such fears (Donoghue et al. 2009). Similarly, it has been claimed that characteristic mycolic acids can 
be detected in a high through-put mass spectrometric method for the detection of ancient tuberculosis 
(Mark et al. 2010). However, the recorded profiles did not correspond to previously recorded total M. tu-
berculosis mycolic acid profiles (Laval et al. 2001), on which the procedure was based. Indeed, analysis of 
commercial standard mycolic acids did not even produce a recognizable profile. It cannot be concluded 
that a positive diagnosis of ancient tuberculosis was achieved by Mark et al. (2010).
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Fig. 2. Reverse phase HPLC of collected PBA-PFB derivatives of MAs. a, α-Mycolate fraction. b, Methoxy-
mycolate fraction. c, Ketomycolate fraction. See Table 1 for origin of samples 1 to 12. “TB std” and “Lep std” 
are standard mycolic acid profiles for M. tuberculosis and M. leprae, respectively. Unusual peaks are indicated 
by “?”.
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